Liufu Deng

China Pharmaceutical University — China

Immunology and Microbiology · Life Sciences

24h-index9.5kcitations45works5.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

interferon and immune responses(17), Immune Cell Function and Interaction(13), Cancer Immunotherapy and Biomarkers(12), CAR-T cell therapy research(7), Immunotherapy and Immune Responses(6)

Publications45 total

ZBP1 pathway promotes tumor immunogenicity in the combination of anti-HER2 therapy and epigenetic therapy
Cell Reports·2025Open Access
DRL-MEC-based anti-malicious jamming decision in wireless body area network
2025
Research on the Path of AI-Integrated Database Course Teaching Reform: A Case Study of Guangzhou College of Commerce
国际化教育科学与理论·2025
0795 In vivo genome-wide CRISPR screen identifies key factors modulating antigen-specific CD8+ T cells responses to recombinant MVA viral immunotherapy
Journal of Investigative Dermatology·2025
Study on Evacuation Time of Road Tunnel Fire Considering Evacuation Uncertainty
2025
Radiotherapy enhances anticancer CD8 T cell responses by cGAMP transfer through LRRC8A/C volume-regulated anion channels
Science Immunology·2025· 6 cited
Discovery of Potent STING Inhibitors Bearing a Difluorobenzodioxol Structural Motif as Potent Anti-Inflammatory Agents
Journal of Medicinal Chemistry·2025· 8 cited
Genome mining reveals a highly oxidized bacterial perhydrophenanthrene meroterpenoid smelanic acid
Organic & Biomolecular Chemistry·2025· 1 cited
A DNA‐Modularized STING Agonist with Macrophage‐Selectivity and Programmability for Enhanced Anti‐Tumor Immunotherapy (Adv. Sci. 32/2024)
Advanced Science·2024Open Access
A DNA‐Modularized STING Agonist with Macrophage‐Selectivity and Programmability for Enhanced Anti‐Tumor Immunotherapy
Advanced Science·2024· 19 citedOpen Access
Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?
Cancer Biology and Medicine·2024· 8 citedOpen Access
TIM-3 inhibitors: a promising strategy for tumor immunotherapy
Trends in Molecular Medicine·2024· 8 cited
Cell-intrinsic PD-L1 ablation sustains effector CD8+ T cell responses and promotes antitumor T cell therapy
Cell Reports·2024· 16 citedOpen Access
Noncanonical MAVS signaling restrains dendritic cell–driven antitumor immunity by inhibiting IL-12
Science Immunology·2023· 24 cited
STING signaling promotes NK cell antitumor immunity and maintains a reservoir of TCF-1+ NK cells
Cell Reports·2023· 53 citedOpen Access
STING activation in platelets aggravates septic thrombosis by enhancing platelet activation and granule secretion
Immunity·2023· 106 cited
Photochemically controlled activation of STING by CAIX-targeting photocaged agonists to suppress tumor cell growth
Chemical Science·2023· 17 citedOpen Access
Androgen receptor-mediated CD8+ T cell stemness programs drive sex differences in antitumor immunity
Immunity·2022· 38 cited
Mitotic SENP3 activation couples with cGAS signaling in tumor cells to stimulate anti-tumor immunity
Cell Death and Disease·2022· 11 citedOpen Access
635 Reprogramming the tumor microenvironment by a second-generation recombinant modified vaccinia virus Ankara
Journal of Investigative Dermatology·2022
page 1 of 3Next →

Frequent Co-authors

Yang‐Xin Fu(13), Hua Liang(11), Ralph R. Weichselbaum(10), Lu Lu(8), Xiaochuan Hong(8), Yuanqin Yang(8), Wenwen Li(7), Byron Burnette(6), Lingling Wu(6), Dongqing Cao(6), Thomas E. Darga(4), Xuanming Yang(4), Xiangjiao Meng(4), Xinran Wang(4), Chao Yang(4), Jingsi Jin(4), Jinke Cheng(4), Youqiong Ye(4), Michael A. Beckett(3), Meng Xu(3)